2
Clinical Trials associated with Anti-CD33 CAR-T Cell therapy (iCell Gene Therapeutics)Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD33 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
Clinical Study of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Acute Myeloid Leukemias
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.
100 Clinical Results associated with Anti-CD33 CAR-T Cell therapy (iCell Gene Therapeutics)
100 Translational Medicine associated with Anti-CD33 CAR-T Cell therapy (iCell Gene Therapeutics)
100 Patents (Medical) associated with Anti-CD33 CAR-T Cell therapy (iCell Gene Therapeutics)
100 Deals associated with Anti-CD33 CAR-T Cell therapy (iCell Gene Therapeutics)